Ocular mucous membrane pemphigoid: novel treatment strategies.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
17
7
2021
medline:
15
12
2021
entrez:
16
7
2021
Statut:
ppublish
Résumé
To describe current treatments of ocular mucous membrane pemphigoid (OMMP), including conventional systemic immunosuppression (CIST) and novel biologic agents. CIST remains the main stay therapy for the management of OMMP. The choice of agents is tailored to disease severity - mild disease is treated with dapsone, whereas moderately severe cases are often treated with mycophenolate mofetil or sulfa-based drugs and severe cases are treated with cyclophosphamide. In recalcitrant disease newer biologics such as Rituximab, intravenous immunoglobins and tumour necrosis alpha antagonists have proven to be effective in disease control. Control of inflammation with topical therapy and halting conjunctival fibrosis remain as areas of unmet clinical needs. OMMP is largely treated with CIST. The recent introduction of new biologic agents could shape the way the disease is treated in the near future.
Identifiants
pubmed: 34269741
doi: 10.1097/ACI.0000000000000767
pii: 00130832-202110000-00012
doi:
Substances chimiques
Biological Products
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
486-492Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370–379.
Taurone S, Spoletini M, Ralli M, et al. Ocular mucous membrane pemphigoid: a review. Immunol Res 2019; 67:280–289.
Aketa N, Yamaguchi T, Asato T, et al. Elevated aqueous cytokine levels in eyes with ocular surface diseases. Am J Ophthalmol 2017; 184:42–51.
Dart JK. The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on. Eye 2017; 31:301–332.
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381:320–332.
Rauz S, Maddison PG, Dart JKG. Evaluation of mucous membrane pemphigoid with ocular involvement in young patients. Ophthalmology 2005; 112:1268–1274.
Ong HS, Setterfield JF, Minassian DC, Dart JK, Mucous Membrane Pemphigoid Study Group. Mucous membrane pemphigoid with ocular involvement: the clinical phenotype and its relationship to direct immunofluorescence findings. Ophthalmology 2018; 125:496–504.
Coco G, Romano V, Menassa N, et al. Conjunctival biopsy site in mucous membrane pemphigoid. Am J Ophthalmol 2020; 216:1–6.
Dart J, Setterfield J, Groves RW, et al. Autoantibody detection for diagnosis in direct immunofluorescence-negative mucous membrane pemphigoid: ocular and other sites compared. Ophthalmology 2021; 128:372–382. doi:10.1016/j.ophtha.2020.07.052.
doi: 10.1016/j.ophtha.2020.07.052
Mondino BJ, Brown SI, Lempert S, Jenkins MS. The acute manifestations of ocular cicatricial pemphigoid: diagnosis and treatment. Ophthalmology 1979; 86:543–555. doi: 10.1016/s0161-6420(79)35486-0. PMID: 537759.
doi: 10.1016/s0161-6420(79)35486-0.
Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115: 253-261.e1. doi: 10.1016/j.ophtha.2007.04.027. Epub 2007 Jul 26. PMID: 17655931.
doi: 10.1016/j.ophtha.2007.04.027.
Williams GP, Radford C, Nightingale P, et al. Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. Eye 2011; 25:1207–1218. doi: 10.1038/eye.2011.175. Epub 2011 Jul 29. PMID: 21799523; PMCID: PMC3173873.
doi: 10.1038/eye.2011.175.
Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983; 96:453–459. doi: 10.1016/s0002-9394(14)77908-5. PMID: 6353928.
doi: 10.1016/s0002-9394(14)77908-5.
Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008; 115: 2146-2152.e1. doi: 10.1016/j.ophtha.2008.08.002. Epub 2008 Oct 18. PMID: 18930554.
doi: 10.1016/j.ophtha.2008.08.002.
Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6:215–223. doi: 10.1016/s0190-9622(82)70014-3. PMID: 7037880.
doi: 10.1016/s0190-9622(82)70014-3.
Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991; 10:185–195. doi: 10.1097/00003226-199105000-00001. PMID: 2055022.
doi: 10.1097/00003226-199105000-00001.
Doan S, Lerouic JF, Robin H, Prost C, et al. Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology 2001; 108:1565–1568. doi: 10.1016/s0161-6420(01)00657-1. PMID: 11535451.
doi: 10.1016/s0161-6420(01)00657-1.
Elder MJ, Leonard J, Dart JK. Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80:549–552. doi: 10.1136/bjo.80.6.549. PMID: 8759268; PMCID: PMC505530.
doi: 10.1136/bjo.80.6.549.
Sobolewska B, Deuter C, Zierhut M. Current medical treatment of ocular mucous membrane pemphigoid. Ocul Surf 2013; 11:259–266. doi: 10.1016/j.jtos.2013.02.003. Epub 2013 Jul 9. PMID: 24112229.
doi: 10.1016/j.jtos.2013.02.003.
Zurdel J, Aboalchamat B, Zierhut M, et al. Erste klinische Erfahrungen mit Mycophenolatmofetil bei der immunsuppressiven Therapie des okulären Pemphigoids [Early clinical results with mycophenolate mofetil in immunosuppressive therapy of ocular pemphigoid]. Klin Monbl Augenheilkd 2001; 218:222–228. German. doi: 10.1055/s-2001-14917. PMID: 11392266.
doi: 10.1055/s-2001-14917.
Kakuta R, Yamagami J, Funakoshi T, et al. Azathioprine monotherapy in autoimmune blistering diseases: A feasible option for mild to moderate cases. J Dermatol 2018; 45:334–339. doi:10.1111/1346-8138.14173.
doi: 10.1111/1346-8138.14173
McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004; 111:796–801. doi: 10.1016/j.ophtha.2003.07.010. PMID: 15051215.
doi: 10.1016/j.ophtha.2003.07.010.
Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527–663. PMID: 3296406; PMCID: PMC1298749.
Elder MJ, Lightman S, Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 1995; 79:264–266. doi: 10.1136/bjo.79.3.264. PMID: 7703207; PMCID: PMC505076.
doi: 10.1136/bjo.79.3.264.
Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004; 111:960–965. doi:10.1016/j.ophtha.2003.08.034.
doi: 10.1016/j.ophtha.2003.08.034
You C, Ma L, Anesi SD, Stephen Foster C. Long-term remission of ocular cicatricial pemphigoid off immunomodulatory therapy. Eur J Ophthalmol 2018; 28:157–162. doi:10.5301/ejo.5001050.
doi: 10.5301/ejo.5001050
Shifera AS, Hong GH, Khan IR, et al. Disease relapse after drug-free remission in ocular mucous membrane pemphigoid. Am J Ophthalmol 2021; 223:21–27. doi:10.1016/j.ajo.2020.09.029.
doi: 10.1016/j.ajo.2020.09.029
Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993; 12:413–419.
Michel J-L, Gain P. Topical tacrolimus treatment for ocular cicatricial pemphigoid. Ann Dermatol Venereol 2006; 133:161–164.
Lytvyn Y, Rahat S, Mufti A, et al. Biologic treatment outcomes in mucous membrane pemphigoid: a systematic review [published online ahead of print, 2021 Jan 7]. J Am Acad Dermatol 2021; S0190-9622(21)00010-4. doi:10.1016/j.jaad.2020.12.056.
doi: 10.1016/j.jaad.2020.12.056
Maley A, Warren M, Haberman I, et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 2016; 74:835–840. doi: 10.1016/j.jaad.2016.01.020. Epub 2016 Feb 28. PMID: 26936298.
doi: 10.1016/j.jaad.2016.01.020.
Rübsam A, Stefaniak R, Worm M, Pleyer U. Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther 2015; 15:927–933. doi: 10.1517/14712598.2015.1046833. Epub 2015 May 12. PMID: 25966960.
doi: 10.1517/14712598.2015.1046833.
Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2011; 25:1238–1240. doi: 10.1111/j.1468-3083.2010.03889.x. Epub 2010 Nov 4. PMID: 21054575.
doi: 10.1111/j.1468-3083.2010.03889.x.
Schumann T, Schmidt E, Booken N, et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol 2009; 89:101–102. doi: 10.2340/00015555-0560. PMID: 19197558.
doi: 10.2340/00015555-0560.
Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. Clin Dermatol 2020; 38:384–396. doi:10.1016/j.clindermatol.2019.07.023.
doi: 10.1016/j.clindermatol.2019.07.023
Tovanabutra N, Payne AS. Clinical outcome and safety of rituximab therapy for pemphigoid diseases. J Am Acad Dermatol 2020; 82:1237–1239. doi:10.1016/j.jaad.2019.11.023.
doi: 10.1016/j.jaad.2019.11.023
Flores-Climente V, Rozas-Muñoz E, Martínez-Grau A, et al. Childhood ocular mucous membrane pemphigoid successfully treated with rituximab. Pediatr Dermatol 2019; 36:984–985. doi:10.1111/pde.13971.
doi: 10.1111/pde.13971
Witte M, Zillikens D, Shimanovich I. Intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid. J Eur Acad Dermatol Venereol 2018; 32:e321–e324. doi:10.1111/jdv.14873.
doi: 10.1111/jdv.14873
Steger B, Madhusudan S, Kaye SB, et al. Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis-an interventional case series. Cornea 2016; 35:1611–1614. doi:10.1097/ICO.0000000000001024.
doi: 10.1097/ICO.0000000000001024
Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117:861–869. doi: 10.1016/j.ophtha.2009.09.049. Epub 2010 Jan 4. PMID: 20045562.
doi: 10.1016/j.ophtha.2009.09.049.
Cordero Coma M, Yilmaz T, Foster CS. Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid. Acta Ophthalmol Scand 2007; 85:753–755. doi: 10.1111/j.1600-0420.2007.00941.x. Epub 2007 May 4. PMID: 17488321.
doi: 10.1111/j.1600-0420.2007.00941.x.
John H, Whallett A, Quinlan M. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha. Eye 2007; 21:1434–1435. doi: 10.1038/sj.eye.6702948. Epub 2007 Aug 10. PMID: 17693996.
doi: 10.1038/sj.eye.6702948.
Prey S, Robert PY, Drouet M, et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol 2007; 87:74–75. doi: 10.2340/00015555-0132. PMID: 17225020.
doi: 10.2340/00015555-0132.
Sacher C, Rubbert A, König C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002; 46:113–115. doi: 10.1067/mjd.2001.119100. PMID: 11756956.
doi: 10.1067/mjd.2001.119100.
Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 2006; 142:1268–1270. doi: 10.1001/archderm.142.10.1268. PMID: 17043180.
doi: 10.1001/archderm.142.10.1268.
El Darouti MA, Fakhry Khattab MA, Hegazy RA, et al. Pentoxifylline (antitumor necrosis factor drug): effective adjuvant therapy in the control of ocular cicatricial pemphigoid. Eur J Ophthalmol 2011; 21:529–537. doi:10.5301/EJO.2011.6294.
doi: 10.5301/EJO.2011.6294
Sharon Y, Chu DS. Adrenocorticotropic hormone analogue as novel treatment regimen in ocular cicatricial pemphigoid. Am J Ophthalmol Case Rep 2018; 10:264–267. doi: 10.1016/j.ajoc.2018.03.018. PMID: 29780948; PMCID: PMC5956726.
doi: 10.1016/j.ajoc.2018.03.018.
Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. Am J Ophthalmol 1996; 122:38–52. doi:10.1016/s0002-9394(14)71962-2.
doi: 10.1016/s0002-9394(14)71962-2
Sotozono C, Inatomi T, Nakamura T, et al. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. Acta Ophthalmol 2014; 92:e447–e453. doi:10.1111/aos.12397.
doi: 10.1111/aos.12397
Kochan AS, Hille K, Zahnert B, et al. Osteo-odonto-keratoprosthesis restores vision in ocular mucous membrane pemphigoid. J Dtsch Dermatol Ges 2021; 19:129–132. doi: 10.1111/ddg.14259. Epub 2020 Sep 10. PMID: 32909368.
doi: 10.1111/ddg.14259.
Camacho L, Soldevila A, Fideliz de la Paz M. Transmucosal boston keratoprosthesis type I in a patient with advanced ocular cicatricial pemphigoid. Cornea 2020; 39:1563–1565. doi: 10.1097/ICO.0000000000002413. PMID: 32881715.
doi: 10.1097/ICO.0000000000002413.
Dohlman CH, Terada H. Keratoprosthesis in pemphigoid and Stevens-Johnson syndrome. Adv Exp Med Biol 1998; 438:1021–1025. doi: 10.1007/978-1-4615-5359-5_148. PMID: 9635006.
doi: 10.1007/978-1-4615-5359-5_148.
Geerling G, Dart JK. Management and outcome of cataract surgery in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol 2000; 238:112–118.